Pipeline
Program/Target Prog/Tgt | Indications Inds | Discovery Discov | Preclinical Preclin | Clinical Clin | Current Status Status | |
|---|---|---|---|---|---|---|
Breast Cancer & Solid Tumors | ||||||
Breast Cancer & Solid Tumors | Phase 1 enrolling | |||||
OKI-219 is being investigated in the PIKture-01 clinical trial. PIKture-01 is a First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and in Combination with Endocrine Therapy or HER2-Targeted Therapy in Participants with Advanced Breast Cancer. Additional information about PIKture-01 may be found at www.ClinicalTrials.gov, using Identifier NCT06239467 | ||||||
OKI-TBD | ||||||
Breast Cancer & Solid Tumors | ||||||
OKI-TBD PI3KαH1047X (next gen) selective inhibitor | Breast Cancer & Solid Tumors | Candidate selection | ||||
OKI-TBD | ||||||
Breast Cancer & Solid Tumors | ||||||
OKI-TBD PI3Kα E542K, E545K selective inhibitor | Breast Cancer & Solid Tumors | Active discovery | ||||